{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016657","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.170994+00:00","generated_at":"2026-06-24T01:02:07.278909+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Graphite Bio doses first patient with nula-cel for sickle cell disease; proof-of-concept data mid-2023","bullets":["First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.","Nula-cel is a gene editing therapy designed to directly correct the SCD mutation and restore healthy hemoglobin.","Initial proof-of-concept data from the CEDAR trial expected in mid-2023.","FDA granted Fast Track and Orphan Drug designations for nula-cel.","Phase 1/2 trial to enroll ~15 patients with severe SCD at multiple U.S. sites."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016657","json":"https://secwatch.observer/filing/0000950170-22-016657.json","markdown":"https://secwatch.observer/filing/0000950170-22-016657.md","text":"https://secwatch.observer/filing/0000950170-22-016657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/0000950170-22-016657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/grph-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:02:07.278909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}